Hoth Therapeutics, Inc.

NasdaqCM:HOTH Stock Report

Market Cap: US$13.2m

Hoth Therapeutics Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Robb Knie

Chief executive officer

US$1.9m

Total compensation

CEO salary percentage25.17%
CEO tenure9yrs
CEO ownership2.9%
Management average tenure7.2yrs
Board average tenure6.1yrs

Recent management updates

Recent updates

Analysis Article • Sep 08

Hoth Therapeutics (NASDAQ: HOTH): Small-Cap Biotech Pairing Clinical Breakthroughs with AI Innovation

Hoth Therapeutics (NASDAQ: HOTH) is emerging as one of the most intriguing small-cap biotech stories on the market. With a market capitalization of just ~$16 million, the company is combining tangible clinical success with cutting-edge AI tools, creating a potentially asymmetric investment opportunity.
Analysis Article • Sep 05

Weekly Picks: 💸 A fintech heavyweight with even more upside potential and 2 more picks

This week’s picks cover: Why Venmo and merchant solutions are driving PayPal’s upside potential, how IREN’s pivot from Bitcoin mining to AI infrastructure is adding value, and how Cadeler’s fleet expansion rides offshore wind growth.
Narrative Update • Sep 05

100% Patient Improvement in trial puts this $16M Biotech on the radar

Strengthening Pipeline with Breakthrough AI Hoth Therapeutics (NASDAQ: HOTH) is layering cutting-edge technology on top of its strong clinical momentum. Already known for its standout Phase 2 trial results (100% patient improvement with HT-001 cancer rash trial), Hoth is now integrating Lantern Pharma’s PredictBBB.ai platform , an AI tool with 94% accuracy in predicting whether drugs can cross the blood–brain barrier (BBB).
New Narrative • Sep 01

100% Patient Improvement in trial puts this $16M Biotech on the radar

Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Seeking Alpha • Sep 20

Hoth Therapeutics partners with Altasciences to manufacture HT-TBI for brain injury

Hoth Therapeutics (NASDAQ:HOTH) said on Tuesday it had signed an agreement with Altasciences to develop and manufacture the HT-TBI drug product formulation for the treatment and/or prevention of secondary brain injury. HT-TBI will be developed as a ready-to-use drug-device combination product for use in non-healthcare settings by patients and caregivers at risk for stroke/TBI, emergency healthcare professionals, and military personnel. "We are leveraging Altasciences' expertise to develop and manufacture novel parenteral formulations to achieve a formulation that requires no preparation or special storage requirements to ensure HT-TBI can be used anywhere in the field at the time a head injury or stroke occurs," the company said.
Seeking Alpha • Jun 29

Hoth Therapeutics granted grace days by Nasdaq to regain compliance with bid price rule

Nasdaq has granted Hoth Therapeutics (NASDAQ:HOTH) an additional 180-days or until December 26, 2022 to regain compliance with minimum $1.00 closing bid price per share requirement. In a letter dated December 30, 2021, the company was notified that the minimum bid price per share for its common shares has been below $1.00 for a period of 30 consecutive business days and it no longer meets the minimum bid price requirements. The company having provided written notice of its intention to cure the deficiency during the Additional Compliance Period, including by effecting a reverse stock split, if necessary. If the company does not comply with the minimum bid price requirement during the 180-day grace period than its shares are subject to delisting. Shares plunged around 72% over a period of one year.

CEO Compensation Analysis

How has Robb Knie's remuneration changed compared to Hoth Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$12m

Dec 31 2025US$2mUS$486k

-US$12m

Sep 30 2025n/an/a

-US$12m

Jun 30 2025n/an/a

-US$10m

Mar 31 2025n/an/a

-US$10m

Dec 31 2024US$1mUS$450k

-US$8m

Sep 30 2024n/an/a

-US$8m

Jun 30 2024n/an/a

-US$8m

Mar 31 2024n/an/a

-US$8m

Dec 31 2023US$846kUS$450k

-US$8m

Sep 30 2023n/an/a

-US$10m

Jun 30 2023n/an/a

-US$10m

Mar 31 2023n/an/a

-US$11m

Dec 31 2022US$1mUS$450k

-US$11m

Sep 30 2022n/an/a

-US$11m

Jun 30 2022n/an/a

-US$12m

Mar 31 2022n/an/a

-US$13m

Dec 31 2021US$1mUS$400k

-US$14m

Sep 30 2021n/an/a

-US$12m

Jun 30 2021n/an/a

-US$10m

Mar 31 2021n/an/a

-US$10m

Dec 31 2020US$781kUS$350k

-US$7m

Sep 30 2020n/an/a

-US$10m

Jun 30 2020n/an/a

-US$10m

Mar 31 2020n/an/a

-US$9m

Dec 31 2019US$2mUS$350k

-US$8m

Compensation vs Market: Robb's total compensation ($USD1.93M) is above average for companies of similar size in the US market ($USD626.93K).

Compensation vs Earnings: Robb's compensation has increased whilst the company is unprofitable.

CEO

Robb Knie (56 yo)

9yrs
Tenure
US$1,930,080
Compensation

Mr. Robb Knie is Founder of Hoth Therapeutics, Inc. Mr. Knie served as the Chief Executive Officer, Chief Financial Officer and Chairman of the Board of Directors of FoxWayne Enterprises Acquisition Corp....

Leadership Team

NamePositionTenureCompensationOwnership
Robb Knie
Founder9yrsUS$1.93m2.86%
$ 377.7k
David Briones
Chief Financial Officer7.2yrsno datano data
Hayley Springer
Executive Vice President of Operations4yrsno datano data
7.2yrs
Average Tenure

Experienced Management: HOTH's management team is seasoned and experienced (7.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Robb Knie
Founder9yrsUS$1.93m2.86%
$ 377.7k
Adam Friedman
Member of Scientific Advisory Board8.8yrsno datano data
Mario Lacouture
Member of Scientific Advisory Board5.3yrsno datano data
John Cirrito
Member of Scientific Advisory Board4.3yrsno datano data
David Sarnoff
Independent Director7.8yrsUS$50.00k0.0052%
$ 690.3
William Weglicki
Member of Scientific Advisory Board6.4yrsno datano data
Wayne Linsley
Independent Director6.1yrsUS$56.00k0.00070%
$ 92.4
Glenn Cruse
Member of Scientific Advisory Board6.3yrsno datano data
Sergio Traversa
Member of Scientific Advisory Boardno datano datano data
Jeff Pavell
Independent Director3.4yrsUS$50.00k0.027%
$ 3.5k
Carla Yuede
Member of Scientific Advisory Board4.3yrsno datano data
Christopher Camarra
Independent Director1yrUS$32.36kno data
6.1yrs
Average Tenure
57yo
Average Age

Experienced Board: HOTH's board of directors are considered experienced (6.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/26 18:40
End of Day Share Price 2026/05/22 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Hoth Therapeutics, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason KolbertD. Boral Capital LLC.